Journals / Klinik Psikofarmakoloji Bülteni / 2001 / Cilt: 11 - Sayı: 1

Moklobemid-klomipramin etkileşimi nedenli serotonin sendromu

Serotonin syndrome caused by moclobemide-clomipramine interaction

Pages
33–36
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As we observed and as reported in the recent literature, the most significant adverse effects during anti-depressive therapy appear to be drug interactions between clomipramine and moclobemide which could be fatal.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The serotonin syndrome is due to serotoninergic hyperstimulation, which is caused, mostly, by the interaction between a serotoninergic agent and a serotonin-enhancing drug, in particular the monoaminooxidase inhibitors.
📊
Key Findings & Data:A male patient, 21 years old, with presenting symptoms and findings as unconsciousness, flushing, diaphoresis, tremor, elevated body temperature, disseminated muscular rigidity and increased salivation is reported.
💡
Conclusion & Impact:As we observed and as reported in the recent literature, the most significant adverse effects during anti-depressive therapy appear to be drug interactions between clomipramine and moclobemide which could be fatal.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The serotonin syndrome is due to serotoninergic hyperstimulation, which is caused, mostly, by the interaction between a serotoninergic agent and a serotonin-enhancing drug, in particular the monoaminooxidase inhibitors. A male patient, 21 years old, with presenting symptoms and findings as unconsciousness, flushing, diaphoresis, tremor, elevated body temperature, disseminated muscular rigidity and increased salivation is reported. In the ICU, supportive treatment were applied. After his conscious was normalized, the patient explained that he had taken 900 mg moclobemide and 150 mg clomipramine together to provide strong effect on his depression. This patient was accepted as serotonin syndrome and rhabdomyolysis related to this syndrome, induced by moclobemide plus clomipramine interaction. Also history, laboratory and clinical data confirmed the diagnosis of serotonin syndrome according to Sternbach's criteria. As we observed and as reported in the recent literature, the most significant adverse effects during anti-depressive therapy appear to be drug interactions between clomipramine and moclobemide which could be fatal.

Özet

Serotonerjik hiperstimülasyonla oluşan serotonin sendromu en fazla serotonerjik bir ajan ve özellikle monoaminoksidaz inhibitörleri olmak üzere serotonin arttırıcı bir ilaç arasındaki etkileşim nedeniyle ortaya çıkar 21 yaşında bir erkek hasta, bilinçsizlik, kızarıklık terleme, titreme, beden ısısında yükselme, yaygın müsküler sertlik ve artmış. tükrük salgısı yakınma ve bulguları mevcuttu. Yoğun bakım ünitesinde destekleyici tedavi uygulandı Daha sonra bilinci normale dönen hasta, depresyonuna etkisini güçlendirmesi için 900 mg moklobemid ve 150 mg klomipramini birlikte aldığını belirtti. Hastanın tanısı moklobemid ve klomipramin etkileşiminin neden olduğu serotonin sendromu ve bu sendromla ilişkili rabdomiyoliz olarak kabul edildi. Keza anamnez, laboratuvar ve klinik veriler de Sternbach'ın kriterlerine göre serotonin sendromu tanısını doğruluyordu Gözlemlediğmiz ve yeni literatürde bildirildiği kadarıyla antidepresif tedavi sırasıda en önemli yan etkiler moklobemid ve klomipramin arasındaki ölümcül olabilen ilaç etkileşimleri olarak görünmektedir.

🔖

Cite This Article

KÜÇÜKARDALI, Y., NALBANT, S., TOP, C., ÇANKIR, Z., DANACI, M., EVRENKAYA, R., EBRİNÇ, S., BAŞOĞLU, C. (2022). Moklobemid-klomipramin etkileşimi nedenli serotonin sendromu. Klinik Psikofarmakoloji Bülteni, Cilt: 11 - Sayı: 1, 33–36. https://ajindex.com/articles/574534

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Hilton SE, Maradit H, Moller HJ: Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci 1997
  2. 9 2. Sternbach H: The serotonin syndrome. Am J Psychiatry 1991
  3. 13 3. Kudo K, Sasaki I, Tsuchiyama K, Akiyoshi J, Nagayama H, Fuji I: Serotonin syndrome during clomipramine monoterapy: Comparison of the two diagnostıc criteria. Psychiatry Clin Neurosci 1997
  4. 6 4. Lotufo-Neto F, Rtivedi M, Thase M: Meta analysis of the reversible ınhibitor of MAO type A Moclobemide and Brofomomine for the treatment of depression. Neuropsychopharmacology 1999
  5. 47 5. Fulton B, Benfield P: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 1996
  6. 74 6. Nair NP, Ahmed SK, Kin NM. Biochemistry and pharmacology of reversible inhibitors of MAO-A:focus moclobemide. J Psychiatry Neurosci 1993
  7. 25 7. Haefely W, Burkard WP, Cesura AM at all. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 1992
  8. 14 8. Versiani M, Nardi AE, Figueira IL, Stabl M: Tolerability of moclobemide, a new reversible inhibitor of MAO-A compared with other antidepressants and plasebo. Acta Psychiatry Scand 1990
  9. 8 9. Nowakowska E, Chodera A: Inhıbitor monoamine oxidase of the new generation. Pol Merkuriusz Lek 1997
  10. 4 10. Mayersohn M, Guentert TW: Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995
  11. 332 11. Hetzel W: Safety of moclobemide taken in overdose for attempted suicide. Psychopharma. Suppl.1992
  12. 9 12. Iwersen S, Schmoldt A: Three suicide attempts with moclobemide. J Toxicol Clin Toxicol 1996
  13. 225 13. Myrenfors PG, Eriksson T, Sandstedt CS, Sjobert G. Moclobemide overdose J Intern Med 1993
  14. 115 14. Kuisma MJ: Fatal serotonin syndrome with trismus. ANN emerg MED 1995
  15. 108 15. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemidecitalopram or moclobemide-clomipramine overdose. Lancet 1993
  16. 1419 16. Power BNM, Pinder M, Hackett LP, Ilett KF. Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intensive Care. 1995
  17. 502 17. Froncois B, Marquet P, Desachy A, Roustan J, Lachatre G, Gastinne H.Serotonin syndrome due to an over dose moclobemide and clomipramine. A potantially lifethreatening association. Intensive Care Med 1997
  18. 4 18. Kaplan HI,Benjamin JS.